PTAB Invalidates Antecip's Bone Treatment Patent

By Dani Kass (November 16, 2018, 8:25 PM EST) -- The Patent Trial and Appeal Board has wiped out an entire Antecip Bioventures II LLC patent covering a drug used to treat bone problems, a ruling that came in a post-grant review prompted by Grunenthal GmbH.

The board on Wednesday invalidated the 30-claim patent citing anticipation, obviousness and lack of enablement. One judge dissented from the enablement decision, but agreed the patent should be invalidated as obvious and anticipated.

The patent covers zoledronic acid, which the PTAB described as having "a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!